胃癌CDK2表达及其与临床病理预后特点的关系及NRS-2002评价胃癌患者术前营养风险的初步探索
|
摘要
目的：本研究探讨CDK2表达与胃癌临床、病理特点及预后的关系。
方法：收集2002年6月至2003年1月间行手术治疗的67例胃癌标本,采用免疫组织化学方法检测CDK2的表达情况,并评价癌组织与癌旁组织CDK2表达与患者临床病理以及预后的相关性。
结果：胃癌组织和癌旁组织CDK2的表达率分别为77.6%、58.2%,存在差异,P=0.026。CDK2表达率在患者临床病理特点各组间无差异。癌组织CDK2表达率在患者的总体生存和无瘤生存组间无差异。TNM分期较早的患者与分期较晚的在生存期及无瘤生存期水平存在差异,P<0.05。
结论：CDK2在胃癌癌组织的表达率较癌旁组织明显增高,提示CDK2表达与胃癌的发生有关；未发现癌组织CDK2表达与患者的临床病理、总体生存和无瘤生存有关；TNM分期是决定胃癌患者预后的重要因素。
目的：应用NRS-2002营养风险筛查评分,研究胃癌患者营养风险的发生率,并探讨营养风险同营养支持应用情况及卫生经济学指标的关系。
方法：采用前瞻性研究方法,对2008年10月至2010年4月期间基本外科入院的胃癌患者进行NRS-2002营养风险筛查,并记录营养支持应用情况及卫生经济学相关指标。
结果：胃癌营养风险发生率(NRS2002评分大于或者等于3分)62.8%,其中高风险(评分3-4分)18.8%,低风险(评分5-7分)43.9%,老年患者(年龄大于或者等于65岁)营养发生率86.0%。老年患者药品费用明显高于非老年患者,P=0.016。有营养风险患者住院时间、医疗费用,明显高于无营养风险患者,P值均<0.05；评分为高风险患者医疗费用明显高于低风险患者,P值<0.05。有营养风险患者,尤其老年患者,术前营养支持其住院时间、医疗费用明显低于无营养支持者,P值均<0.05。
结论：胃癌患者营养风险发生率为62.8%,其中以老年患者尤为明显(86.0%)；有营养风险患者,医疗花费和住院时间增高,尤其高风险患者；有营养风险患者,尤其老年患者术前营养支持可减少住院时间和医疗花费；术前营养支持能使有营养风险患者,尤其是老年患者和高风险受益。
Objective:To evaluate correlations between CDK2expression and patients' clinicopathological factors and prognosis in gastric cancer.
Methods:A total of67patients with gastric cancer underwent surgical resection from Jun2002to Jan2003were included. Expression of CDK2in tumor and para-tumor tissues was determined by immunohistochemistry. The relationship between CDK2expression and clinicopathological and prognostic variables were evaluated.
Results:The expression ratios of CDK2in tumor and para-tumor tissues were77.6%and58.2%,statistical difference in them, P=0.026. The expression of CDK2in tumor tissues and para-tumor tissues has no ralationship with clinicopathological characteristic. Univariate analysis showed that patients with negative CDK2expression in tumor tissues had no significantly prolonged overall and tumor-free survival, compared with those with positive expression. TNM stage was correlated with patient prognosis, patients of an early stage had a significantly prolonged overall and tumor-free survival, compared with those of a later stage.
Conclusions:Our data demonstrated that the expression of CDK2in tumor tissues is higher than para-tumor tissues. The finding indicated that CDK2might be involved in tumorigenesis of gastric cancer. Second, CDK2was not correlated with clinicopathological variables and patient prognosis. Finally, TNM stage was important for patient prognosis.
Objective:The aim of this study was to evaluate the rate of nutrition risk in patients with gastric cancer by NRS-2002, to assess the correlations between nutrition risk and applications of nutrition support and health economical indexes.
Methods:In this prospective study, patients in general surgery department were included from Oct2009to Apr2010. Patients received nutrition risk screening2002at the admission. Data aslo was recorded on applications of nutrition support and health economical indexes.
Results:The average rate of nutrition risk in gastric cancer was62.8%, including high risk18.8%, low risk43.9%. The rate in elderly patients was86.0%. The drug expenses of elderly patients was different to not elderly, P=0.016. The hospitalized time and medical expenses were different between patients with and without nutrition risk, P<0.05, and there existed a difference of medical costs between high risk patients and lower risk, P<0.05. Compared with those without preoperation nutrition support, hospitalized time and medical expenses at nutrition risk showed a difference in patients received nutrition support, especially for elderly ones, P<0.05.
Conclutions:Patients with gastric cancer, especially elderly ones, had a high rate of nutrition risk. Those with nutrition risk had higher hospitalized time and medical expenses especially high risk patients. For patients, especially elderly and high risk ones with nutrition risk, the preoperative nutritional support could reduce the time and the expenses.
方法：收集2002年6月至2003年1月间行手术治疗的67例胃癌标本,采用免疫组织化学方法检测CDK2的表达情况,并评价癌组织与癌旁组织CDK2表达与患者临床病理以及预后的相关性。
结果：胃癌组织和癌旁组织CDK2的表达率分别为77.6%、58.2%,存在差异,P=0.026。CDK2表达率在患者临床病理特点各组间无差异。癌组织CDK2表达率在患者的总体生存和无瘤生存组间无差异。TNM分期较早的患者与分期较晚的在生存期及无瘤生存期水平存在差异,P<0.05。
结论：CDK2在胃癌癌组织的表达率较癌旁组织明显增高,提示CDK2表达与胃癌的发生有关；未发现癌组织CDK2表达与患者的临床病理、总体生存和无瘤生存有关；TNM分期是决定胃癌患者预后的重要因素。
目的：应用NRS-2002营养风险筛查评分,研究胃癌患者营养风险的发生率,并探讨营养风险同营养支持应用情况及卫生经济学指标的关系。
方法：采用前瞻性研究方法,对2008年10月至2010年4月期间基本外科入院的胃癌患者进行NRS-2002营养风险筛查,并记录营养支持应用情况及卫生经济学相关指标。
结果：胃癌营养风险发生率(NRS2002评分大于或者等于3分)62.8%,其中高风险(评分3-4分)18.8%,低风险(评分5-7分)43.9%,老年患者(年龄大于或者等于65岁)营养发生率86.0%。老年患者药品费用明显高于非老年患者,P=0.016。有营养风险患者住院时间、医疗费用,明显高于无营养风险患者,P值均<0.05；评分为高风险患者医疗费用明显高于低风险患者,P值<0.05。有营养风险患者,尤其老年患者,术前营养支持其住院时间、医疗费用明显低于无营养支持者,P值均<0.05。
结论：胃癌患者营养风险发生率为62.8%,其中以老年患者尤为明显(86.0%)；有营养风险患者,医疗花费和住院时间增高,尤其高风险患者；有营养风险患者,尤其老年患者术前营养支持可减少住院时间和医疗花费；术前营养支持能使有营养风险患者,尤其是老年患者和高风险受益。
Objective:To evaluate correlations between CDK2expression and patients' clinicopathological factors and prognosis in gastric cancer.
Methods:A total of67patients with gastric cancer underwent surgical resection from Jun2002to Jan2003were included. Expression of CDK2in tumor and para-tumor tissues was determined by immunohistochemistry. The relationship between CDK2expression and clinicopathological and prognostic variables were evaluated.
Results:The expression ratios of CDK2in tumor and para-tumor tissues were77.6%and58.2%,statistical difference in them, P=0.026. The expression of CDK2in tumor tissues and para-tumor tissues has no ralationship with clinicopathological characteristic. Univariate analysis showed that patients with negative CDK2expression in tumor tissues had no significantly prolonged overall and tumor-free survival, compared with those with positive expression. TNM stage was correlated with patient prognosis, patients of an early stage had a significantly prolonged overall and tumor-free survival, compared with those of a later stage.
Conclusions:Our data demonstrated that the expression of CDK2in tumor tissues is higher than para-tumor tissues. The finding indicated that CDK2might be involved in tumorigenesis of gastric cancer. Second, CDK2was not correlated with clinicopathological variables and patient prognosis. Finally, TNM stage was important for patient prognosis.
Objective:The aim of this study was to evaluate the rate of nutrition risk in patients with gastric cancer by NRS-2002, to assess the correlations between nutrition risk and applications of nutrition support and health economical indexes.
Methods:In this prospective study, patients in general surgery department were included from Oct2009to Apr2010. Patients received nutrition risk screening2002at the admission. Data aslo was recorded on applications of nutrition support and health economical indexes.
Results:The average rate of nutrition risk in gastric cancer was62.8%, including high risk18.8%, low risk43.9%. The rate in elderly patients was86.0%. The drug expenses of elderly patients was different to not elderly, P=0.016. The hospitalized time and medical expenses were different between patients with and without nutrition risk, P<0.05, and there existed a difference of medical costs between high risk patients and lower risk, P<0.05. Compared with those without preoperation nutrition support, hospitalized time and medical expenses at nutrition risk showed a difference in patients received nutrition support, especially for elderly ones, P<0.05.
Conclutions:Patients with gastric cancer, especially elderly ones, had a high rate of nutrition risk. Those with nutrition risk had higher hospitalized time and medical expenses especially high risk patients. For patients, especially elderly and high risk ones with nutrition risk, the preoperative nutritional support could reduce the time and the expenses.
引文
1. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006,12(1):17-20.
2. Sabiston Textbook of Surgery 18th edition.
3. Yasui W, Oue N, Aung PP, et al. Molecular-pathological prognostic factors of gastric cancer:a review. Gastric Cancer.2005,8(2):86-94.
4. Werner M, Becker KF, Keller G, et al. Gastric adenocarcinoma:pathomorphology and molecular pathology. J Cancer Res Clin Oncol.2001,127(4):207-16.
5. Xiangming C, Natsugoe S, Takao S, et al. The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer.2000,89(6):1214-9.
6. Kondo T, Oue N, Yoshida K, et al. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res.2004,64(2):523-9.
7. Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer.1997,76(4):531-6.
8. van Straaten F, Muller R, Curran T, et al. Complete nucleotide sequence of a human c-onc gene:deduced amino acid sequence of the human c-fos protein. Proc Natl Acad Sci U S A.1983,80(11):3183-7.
9. Ekstrand AJ, Zech L. Human c-fos proto-oncogene mapped to chromosome 14, band q24.3-q31. Possibilities for oncogene activation by chromosomal rearrangements in human neoplasms. ExpCell Res.1987,169(1):262-6.
10. Ming J, Zhang Q, Qiu X, et al. Eur J Cancer. Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation:a mechanism of lymphangiogenesis in lung cancer.2009,45(5):866-73.
11. Vairaktaris E, Papakosta V, Derka S, et al. H-ras and c-fos exhibit similar expression patterns during most stages of oral oncogenesis. In Vivo.2008,22(5):621-8.
12. Jin SP, Kim JH, Kim MA, et al. Prognostic significance of loss of c-fos protein in gastric carcinoma. Pathol Oncol Res.2007,13(4):284-9.
13. Gamberi G, Benassi MS, Bohling T, et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology.1998,55(6):556-63.
14. Bamberger AM, Milde-Langosch K, Rossing E, et al. Expression pattern of the AP-1 family in endometrial cancer:correlations with cell cycle regulators. J Cancer Res Clin Oncol.2001,127(9):545-50.
15. Sherr CJ. Cancer cell cycle.Science 1996;274:1672-1678.
16. Wang S, Evers BM. Cytokine-mediated differential induction of hepatic activator protein-1 genes. Surgery 1998;123:191-198.
17. Iseki H, Ko TC, Xue XY, et al. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer. Surgery 1997; 122:187-195.
18. Scott KA and Walker RA. Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br J cancer 1997;76:1288-1292.
19. Sakaguchi T, Watanabe A, Sawada H, et al. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer 1998;82:1238-1243.
20. Matsumoto M, Furihata M, Ishikawa T, et al. Comparison of deregulated expression of cyclinDl and cyclinE with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squmous cell carcinoma. Br J Cancer 1999;80:256-261.
21. Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin E in human gastric adenomas and adenocarcinomas:correlation with proliferative activity and p53 status. J Exp Ther Oncol 1996; 1:88-94.
22. Liang B, Wang S, Yang XD, et al. Expressions of cyclin E,cyclin dependent kinase 2 and p57 in human gastric cancer. Chin Med J.2003 Jan,116(1):20-23.
23.谢妮.环氧化酶2、细胞周期调节蛋白依赖性激酶CDK2在胃癌中的表达.南华大学学报.2009,37(6)：703-704.
24. Valeria M, Alessandro S, Carmen P, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res,1999,59: 3790-3794.
25. Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E,et al. Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. J Clin Pathol. 2007 Jul;60(7):756-61.
[1]Reference Age stratified mortality rates (1/100,000) secondary to malignant tumors of urban residents in China in 1998,Chinese J Health Statistics 1999,16:310-319. Fuchs CS,Mayer RJ.Gastric carcinoma.N Eng J Med 1995,333:32-41.
[2]Yasui W, et al. Reduced expression of cyclin-dependent kinase inhibitor p27 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res,1997,88: 625
[3]Ohtani M,et al. Impact of the expression of cyclin dependent kinase inhibitor p27 and apoptosis in tumor cells on the over all survival of patients with non-early stage gastric carcinomal Cancer,1999,85:171
[4]LIX,et al. Transactivation of cyclin E gene by EWSFlil and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells[J] Int J Cancer,2005,116 (3): 385-394
[5]TAO Y,et al. Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein Barren coded oncoprotein latent membrane protein [J] Exp Cell Res,2005,303 (2):240-251
[6]XIE RL,et al. The tumor suppressor interferon regulatory factor interferes with SP1 activation to repress the human CDK2 promoter[J]Biol Chem,2003,278 (29):265-274
[7]MINELLAAC,et al. Ras activity regulates cyclin E degradation by the Fbw7 pathway[J] Proc Natl Acad Sci USA,2005,102 (27):9649-9654
[8]SIMKG,et al. TRIP-Br links E2F to novel functions in the regulation of cyclinE expression during cell cycle progression and in the maintenance of genomic stability [J] Cell Cycle,2004,3 (10):1296-1304
[9]MUKHERJEE S,et al. c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells[J] Biol Chem,2005, 280(18):17617-17625
[10]NAKAGAWAM,et al. Phorbolerster induced G1 phase arrest selectively mediated by a PKC delta dependent induction of p21, Biol Chem,2005,280 (40):33926-33934
[11]LIP,et al.p27 (Kip1) stabilization and G(1)arrest by 1,25-dihydroxyvitamin D (3) in ovarian cancer cellsmediated through down regulation of cyclin E/cyclin-dependent kinase2 and Skpl2CullinF box protein/Skp2 ubiquitin ligase,[J]BiolChem,2004,279 (24): 25260-25267
[12]LIU Qi,et al. Preliminary Analysis of CDK2 Sequence and Its Nuclear Import, Acta Genetica SinicaMay,2004,31 (5):444-448
[13]LIANG Bin,et al.Expressions of cyclin E, cyclin dependent kinase 2 and p57 in human gastric cancer, CMJ 2003,116(1):20-23
[14]Ferrando A,et al.Mutational analysis of the human cyclin-dependent kinase inhibitor p27 in primary breast carcinomas Hum Genet,1996,97:91
[15]W Yasui,et al. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinom Cancer Res, Jul 1997, 88 (7):625
[16]Surendra P,et al. Loss or altered subcellula localization of p27 in Barrett's associated adenocarcinoma [J] CancerRes,1997,58:1730-1732.
[17]Loda M,et al. Increased proteasome dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1 in aggressivecolorectal carcinoma[J] Nat Med,1997,3:231-234.
[18]王盛乾等.,p27癌基因蛋白在肝癌和癌旁肝组织中表达的意义研究[J].实用肿瘤杂志,2000,15(3)：155-156
[19]王刚等,滋养细胞疾病中p27Kip1蛋白表达的研究[J],实用肿瘤杂志,200015(3)：199-200.
[20]Mori M, et al. p27 expression and gastric carcinoma. Nat Med 1997;3:593
[21]Ohtani M, et al. Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma. Cancer 1999;85:1711-18.
[22]Takano Y, et al. CyclinD overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 2000; 156:585-94
[23]Joypaul,et al. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994;69:943-6.
[24]Gomyo Y, Ikeda M, Osaki M, et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997;79:2067-72
[25]Armando Gamboa-Dominguez, Prognostic significance of p21 WAF1/C1P1, p27Kip1, p53 and E-cadherin expression in gastric cancer, J Clin Pathol.2007 Jul;60(7):756-61.
1. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006,12(1):17-20.
2. Ward N. Nutrition support to patients undergoing gastrointestinal surgery.Nutrition J, 2003,2(1):18-23.
3. Kyle UG, Kossovsky MP, Karsegard VL, et al. Comparison of tools for nutritional assessment and screening at hospital admission:a population study. Clin Nutr,2006, 25(3):409-417.
4. Bauer JM, Vogl T, Wicklein S, et al. Comparison of the mini nutritional assessment, subjective global assessment, and nutritional risk screening (NRS2002) for nutritional screening and assessment in geriatric hospital patients. Z Gerontol Geriat,2005,38(5): 322-327.
5. Sorenscn J, Kondrup J, Prokopowicz J, et al. EureOOPS:an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. Clin Nutr, 2008,27(3):340-349.
6. Schiesser M, MOiler S, Kirchhoff P, et al. Assessment of a novel screening score for nutritional risk in predicting complications in gastrointestinal surgery. Clin Nutr,2008, 27(4):565-570.
7. Martins CP, Correia JR, Amaral TF. Undernutrition risk screening and length of stay of hospitalized elderly. J Nutr Elder,2005,25(2):5-21.
8. Amaral TF, Matos LC, Tavares MM, et al. The economic impact of disease-related malnutrition at hospital admission. Clin Nutr,2007,26(6):778-784.
9.陈伟,蒋朱明,张永梅,等。欧洲营养不良风险筛查方法在中国住院患者的临床可行性研究。中国临床营养杂志,2005,13(3)：137-141。
10.蒋朱明,陈伟,朱赛楠,等.我国东中部大城市三甲医院营养不良(不足)营养风险发生率及营养支持以用状况调查.中国临床营养杂志,2008,16：335.
11. Kondrup J, Johansen N, Plum LM, et al. Incidence of nutritional risk and causes of inadequate nutritional care in hospitals. Clin Nutr,2002,21 (6):461-468.
12. Kondrup J, Allison SP, Elia M, et al. PSPEN guidelines for nutrition screening 2002.Clin Nutr,2003,22 (4):415-421.
13. Kondrup J, Rasmussen HH, Hamberg O, et al. ESPEN working group(2003) Nutritional risk screening (NRS2002):a new method based on an analysis of controlled clinical trials. Clin Nutr,2003,22 (3):321-336.
14.陈伟,蒋朱明,张咏梅,等.欧洲营养不良风险调查方法在中国住院患者的临床可行性研究.中国临床营养杂志,2005,13(3)：137-141.
15.蒋朱明,陈伟,张澍出,等.中国11个城市大医院6个临床专科5303例住院患者营养不良风险筛查.中国临床营养杂志,2006,14(4)：263.
16. Vanis N, Mesihovic R. Application of nutritional screening tests for determining prevalence of hospital malnutrition. Med Arh,2008,62:211-214.
17. Imoberdorf R, Meier R, Krebs P, et al. Prevalence of undernutrition on admission to Swiss hospitals. Clin Nutr.2010 Feb;29(l):38-41
18. Sorensen J, Kondrup J, Prokopowicz J, et al. EuroOOPS:an international,muhieentre study to implement nutritional risk screening and evaluate clinical outcome. ClinNutr, 2008,27:340-349.
19. Masopust J, Kratoehvil J, Martinkova V, et al. The relation between nutritional risk category identified by the modified Nutritional Screening 2002 and mortality in metabolic intensive care unit. Vnitr Lek,2008,54:817-820.
20. Pritchard C, Dufly S, Edington J, et al. Enteral nutrition and oral nutrition supplements: a review of the economics literature. JPEN J Parenter Enteral Nutr,2006,30(1):52-59.
21. Riehards DM, Irving MH. Cost-utility analysis of home parenteral nutrition. Br J Surg, 1996,83(9):1226-1229.
22.耿建利,王金波,乔建文,等.胃癌手术后早期肠内肠外营养支持效果.中固临床营养杂志,2006,14(6)：374.377.
23.蒋朱明,曹金铎,蔡东联,等.肠内或肠外营养对术后患者肝功能、肠通透性、血谷氨酰胺的影响及费用比较(120例随机、对照、多中心临床研究).中国临床营养杂志,2002,10(1)：6-9.
1. McWhirter JP, Pennington CR. Incidence and recognition of malnutrition in hospital. BMJ.1994,308(6934):945-948.
2. Corish CA, Kennedy NP. Protein-energy undernutrition in hospital inpatients. Br J Nutr, 2000,83(6):575-591.
3. Arrowsmith H. Malnutrition in hospital:detection and consequences. Br J Nuts,1997, 6(19):1131-1135.
4. 崔丽英,陈海波,宿英英,等.北京大医院神经科住院患者营养风险、营养不足、超重和肥胖发生率及营养支持应用状况.中华临床营养杂志,2009,17(2)：67-70.
5.粱晓坤,蒋朱明,Nolan MT.北京教学医院普通外科住院患者营养风险、营养不足、超重、肥胖及营养支持状况.中华临床营养杂志,2009,17(2)：75-78.
6.于康,赵维刚,阮晓兰,等.内分泌科住院患者营养风险筛奁及营养支持应用状况.中华临床营养杂志,2009,17(2)：71-74.
7.张平骥,卞婧,周业平.呼吸内科住院患者营养风险筛查.中华临床营养杂志,2009,17(2)：79-81.
8.张丽娅,尹群芳,苏惠崧.术前营养支持对结肠癌患者术后营养状况、并发症发生率影响的临床观察.医学理论与实践,2008,21(4).
9. Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening NRS 2002:a new method based on an analysis of controlled clinical trials. Clin Nutr, 2003.22:321-336.
10.揭彬,蒋朱明,朱赛楠.营养干预、营养风险对临床结局影响研究的方法学.中国临床营养杂志,2008,16(6)：367-370
11.陈伟,蒋朱明,张水梅,等.欧洲营养不良风险调查方法在中国住院患者的临床可行性研究.中国临床营养杂志,2005,3：137-141.
12.郭卫平,卫洪波,李玺.应用营养风险筛查2002评分系统对胃癌患者术前营养风险的评估.中华普外科杂志,2009,24(10).
13.徐兰娟,曹丽萍.结直肠癌患者的围手术期营养风险筛查与术后并发症.中国临床营养杂志,2009,17(1).
14.康维明,于健春,张群.胃肿瘤术后早期肠内营养的临床观察.外科理论与实践.2004,9(5).
15.王艳,蒋朱明,于康.临床营养的经济学研究进展.临床药物治疗杂志.2009,7(6).
2. Sabiston Textbook of Surgery 18th edition.
3. Yasui W, Oue N, Aung PP, et al. Molecular-pathological prognostic factors of gastric cancer:a review. Gastric Cancer.2005,8(2):86-94.
4. Werner M, Becker KF, Keller G, et al. Gastric adenocarcinoma:pathomorphology and molecular pathology. J Cancer Res Clin Oncol.2001,127(4):207-16.
5. Xiangming C, Natsugoe S, Takao S, et al. The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer.2000,89(6):1214-9.
6. Kondo T, Oue N, Yoshida K, et al. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res.2004,64(2):523-9.
7. Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer.1997,76(4):531-6.
8. van Straaten F, Muller R, Curran T, et al. Complete nucleotide sequence of a human c-onc gene:deduced amino acid sequence of the human c-fos protein. Proc Natl Acad Sci U S A.1983,80(11):3183-7.
9. Ekstrand AJ, Zech L. Human c-fos proto-oncogene mapped to chromosome 14, band q24.3-q31. Possibilities for oncogene activation by chromosomal rearrangements in human neoplasms. ExpCell Res.1987,169(1):262-6.
10. Ming J, Zhang Q, Qiu X, et al. Eur J Cancer. Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation:a mechanism of lymphangiogenesis in lung cancer.2009,45(5):866-73.
11. Vairaktaris E, Papakosta V, Derka S, et al. H-ras and c-fos exhibit similar expression patterns during most stages of oral oncogenesis. In Vivo.2008,22(5):621-8.
12. Jin SP, Kim JH, Kim MA, et al. Prognostic significance of loss of c-fos protein in gastric carcinoma. Pathol Oncol Res.2007,13(4):284-9.
13. Gamberi G, Benassi MS, Bohling T, et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology.1998,55(6):556-63.
14. Bamberger AM, Milde-Langosch K, Rossing E, et al. Expression pattern of the AP-1 family in endometrial cancer:correlations with cell cycle regulators. J Cancer Res Clin Oncol.2001,127(9):545-50.
15. Sherr CJ. Cancer cell cycle.Science 1996;274:1672-1678.
16. Wang S, Evers BM. Cytokine-mediated differential induction of hepatic activator protein-1 genes. Surgery 1998;123:191-198.
17. Iseki H, Ko TC, Xue XY, et al. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer. Surgery 1997; 122:187-195.
18. Scott KA and Walker RA. Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br J cancer 1997;76:1288-1292.
19. Sakaguchi T, Watanabe A, Sawada H, et al. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer 1998;82:1238-1243.
20. Matsumoto M, Furihata M, Ishikawa T, et al. Comparison of deregulated expression of cyclinDl and cyclinE with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squmous cell carcinoma. Br J Cancer 1999;80:256-261.
21. Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin E in human gastric adenomas and adenocarcinomas:correlation with proliferative activity and p53 status. J Exp Ther Oncol 1996; 1:88-94.
22. Liang B, Wang S, Yang XD, et al. Expressions of cyclin E,cyclin dependent kinase 2 and p57 in human gastric cancer. Chin Med J.2003 Jan,116(1):20-23.
23.谢妮.环氧化酶2、细胞周期调节蛋白依赖性激酶CDK2在胃癌中的表达.南华大学学报.2009,37(6)：703-704.
24. Valeria M, Alessandro S, Carmen P, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res,1999,59: 3790-3794.
25. Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E,et al. Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. J Clin Pathol. 2007 Jul;60(7):756-61.
[1]Reference Age stratified mortality rates (1/100,000) secondary to malignant tumors of urban residents in China in 1998,Chinese J Health Statistics 1999,16:310-319. Fuchs CS,Mayer RJ.Gastric carcinoma.N Eng J Med 1995,333:32-41.
[2]Yasui W, et al. Reduced expression of cyclin-dependent kinase inhibitor p27 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res,1997,88: 625
[3]Ohtani M,et al. Impact of the expression of cyclin dependent kinase inhibitor p27 and apoptosis in tumor cells on the over all survival of patients with non-early stage gastric carcinomal Cancer,1999,85:171
[4]LIX,et al. Transactivation of cyclin E gene by EWSFlil and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells[J] Int J Cancer,2005,116 (3): 385-394
[5]TAO Y,et al. Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein Barren coded oncoprotein latent membrane protein [J] Exp Cell Res,2005,303 (2):240-251
[6]XIE RL,et al. The tumor suppressor interferon regulatory factor interferes with SP1 activation to repress the human CDK2 promoter[J]Biol Chem,2003,278 (29):265-274
[7]MINELLAAC,et al. Ras activity regulates cyclin E degradation by the Fbw7 pathway[J] Proc Natl Acad Sci USA,2005,102 (27):9649-9654
[8]SIMKG,et al. TRIP-Br links E2F to novel functions in the regulation of cyclinE expression during cell cycle progression and in the maintenance of genomic stability [J] Cell Cycle,2004,3 (10):1296-1304
[9]MUKHERJEE S,et al. c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells[J] Biol Chem,2005, 280(18):17617-17625
[10]NAKAGAWAM,et al. Phorbolerster induced G1 phase arrest selectively mediated by a PKC delta dependent induction of p21, Biol Chem,2005,280 (40):33926-33934
[11]LIP,et al.p27 (Kip1) stabilization and G(1)arrest by 1,25-dihydroxyvitamin D (3) in ovarian cancer cellsmediated through down regulation of cyclin E/cyclin-dependent kinase2 and Skpl2CullinF box protein/Skp2 ubiquitin ligase,[J]BiolChem,2004,279 (24): 25260-25267
[12]LIU Qi,et al. Preliminary Analysis of CDK2 Sequence and Its Nuclear Import, Acta Genetica SinicaMay,2004,31 (5):444-448
[13]LIANG Bin,et al.Expressions of cyclin E, cyclin dependent kinase 2 and p57 in human gastric cancer, CMJ 2003,116(1):20-23
[14]Ferrando A,et al.Mutational analysis of the human cyclin-dependent kinase inhibitor p27 in primary breast carcinomas Hum Genet,1996,97:91
[15]W Yasui,et al. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinom Cancer Res, Jul 1997, 88 (7):625
[16]Surendra P,et al. Loss or altered subcellula localization of p27 in Barrett's associated adenocarcinoma [J] CancerRes,1997,58:1730-1732.
[17]Loda M,et al. Increased proteasome dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1 in aggressivecolorectal carcinoma[J] Nat Med,1997,3:231-234.
[18]王盛乾等.,p27癌基因蛋白在肝癌和癌旁肝组织中表达的意义研究[J].实用肿瘤杂志,2000,15(3)：155-156
[19]王刚等,滋养细胞疾病中p27Kip1蛋白表达的研究[J],实用肿瘤杂志,200015(3)：199-200.
[20]Mori M, et al. p27 expression and gastric carcinoma. Nat Med 1997;3:593
[21]Ohtani M, et al. Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma. Cancer 1999;85:1711-18.
[22]Takano Y, et al. CyclinD overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 2000; 156:585-94
[23]Joypaul,et al. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994;69:943-6.
[24]Gomyo Y, Ikeda M, Osaki M, et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997;79:2067-72
[25]Armando Gamboa-Dominguez, Prognostic significance of p21 WAF1/C1P1, p27Kip1, p53 and E-cadherin expression in gastric cancer, J Clin Pathol.2007 Jul;60(7):756-61.
1. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006,12(1):17-20.
2. Ward N. Nutrition support to patients undergoing gastrointestinal surgery.Nutrition J, 2003,2(1):18-23.
3. Kyle UG, Kossovsky MP, Karsegard VL, et al. Comparison of tools for nutritional assessment and screening at hospital admission:a population study. Clin Nutr,2006, 25(3):409-417.
4. Bauer JM, Vogl T, Wicklein S, et al. Comparison of the mini nutritional assessment, subjective global assessment, and nutritional risk screening (NRS2002) for nutritional screening and assessment in geriatric hospital patients. Z Gerontol Geriat,2005,38(5): 322-327.
5. Sorenscn J, Kondrup J, Prokopowicz J, et al. EureOOPS:an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. Clin Nutr, 2008,27(3):340-349.
6. Schiesser M, MOiler S, Kirchhoff P, et al. Assessment of a novel screening score for nutritional risk in predicting complications in gastrointestinal surgery. Clin Nutr,2008, 27(4):565-570.
7. Martins CP, Correia JR, Amaral TF. Undernutrition risk screening and length of stay of hospitalized elderly. J Nutr Elder,2005,25(2):5-21.
8. Amaral TF, Matos LC, Tavares MM, et al. The economic impact of disease-related malnutrition at hospital admission. Clin Nutr,2007,26(6):778-784.
9.陈伟,蒋朱明,张永梅,等。欧洲营养不良风险筛查方法在中国住院患者的临床可行性研究。中国临床营养杂志,2005,13(3)：137-141。
10.蒋朱明,陈伟,朱赛楠,等.我国东中部大城市三甲医院营养不良(不足)营养风险发生率及营养支持以用状况调查.中国临床营养杂志,2008,16：335.
11. Kondrup J, Johansen N, Plum LM, et al. Incidence of nutritional risk and causes of inadequate nutritional care in hospitals. Clin Nutr,2002,21 (6):461-468.
12. Kondrup J, Allison SP, Elia M, et al. PSPEN guidelines for nutrition screening 2002.Clin Nutr,2003,22 (4):415-421.
13. Kondrup J, Rasmussen HH, Hamberg O, et al. ESPEN working group(2003) Nutritional risk screening (NRS2002):a new method based on an analysis of controlled clinical trials. Clin Nutr,2003,22 (3):321-336.
14.陈伟,蒋朱明,张咏梅,等.欧洲营养不良风险调查方法在中国住院患者的临床可行性研究.中国临床营养杂志,2005,13(3)：137-141.
15.蒋朱明,陈伟,张澍出,等.中国11个城市大医院6个临床专科5303例住院患者营养不良风险筛查.中国临床营养杂志,2006,14(4)：263.
16. Vanis N, Mesihovic R. Application of nutritional screening tests for determining prevalence of hospital malnutrition. Med Arh,2008,62:211-214.
17. Imoberdorf R, Meier R, Krebs P, et al. Prevalence of undernutrition on admission to Swiss hospitals. Clin Nutr.2010 Feb;29(l):38-41
18. Sorensen J, Kondrup J, Prokopowicz J, et al. EuroOOPS:an international,muhieentre study to implement nutritional risk screening and evaluate clinical outcome. ClinNutr, 2008,27:340-349.
19. Masopust J, Kratoehvil J, Martinkova V, et al. The relation between nutritional risk category identified by the modified Nutritional Screening 2002 and mortality in metabolic intensive care unit. Vnitr Lek,2008,54:817-820.
20. Pritchard C, Dufly S, Edington J, et al. Enteral nutrition and oral nutrition supplements: a review of the economics literature. JPEN J Parenter Enteral Nutr,2006,30(1):52-59.
21. Riehards DM, Irving MH. Cost-utility analysis of home parenteral nutrition. Br J Surg, 1996,83(9):1226-1229.
22.耿建利,王金波,乔建文,等.胃癌手术后早期肠内肠外营养支持效果.中固临床营养杂志,2006,14(6)：374.377.
23.蒋朱明,曹金铎,蔡东联,等.肠内或肠外营养对术后患者肝功能、肠通透性、血谷氨酰胺的影响及费用比较(120例随机、对照、多中心临床研究).中国临床营养杂志,2002,10(1)：6-9.
1. McWhirter JP, Pennington CR. Incidence and recognition of malnutrition in hospital. BMJ.1994,308(6934):945-948.
2. Corish CA, Kennedy NP. Protein-energy undernutrition in hospital inpatients. Br J Nutr, 2000,83(6):575-591.
3. Arrowsmith H. Malnutrition in hospital:detection and consequences. Br J Nuts,1997, 6(19):1131-1135.
4. 崔丽英,陈海波,宿英英,等.北京大医院神经科住院患者营养风险、营养不足、超重和肥胖发生率及营养支持应用状况.中华临床营养杂志,2009,17(2)：67-70.
5.粱晓坤,蒋朱明,Nolan MT.北京教学医院普通外科住院患者营养风险、营养不足、超重、肥胖及营养支持状况.中华临床营养杂志,2009,17(2)：75-78.
6.于康,赵维刚,阮晓兰,等.内分泌科住院患者营养风险筛奁及营养支持应用状况.中华临床营养杂志,2009,17(2)：71-74.
7.张平骥,卞婧,周业平.呼吸内科住院患者营养风险筛查.中华临床营养杂志,2009,17(2)：79-81.
8.张丽娅,尹群芳,苏惠崧.术前营养支持对结肠癌患者术后营养状况、并发症发生率影响的临床观察.医学理论与实践,2008,21(4).
9. Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening NRS 2002:a new method based on an analysis of controlled clinical trials. Clin Nutr, 2003.22:321-336.
10.揭彬,蒋朱明,朱赛楠.营养干预、营养风险对临床结局影响研究的方法学.中国临床营养杂志,2008,16(6)：367-370
11.陈伟,蒋朱明,张水梅,等.欧洲营养不良风险调查方法在中国住院患者的临床可行性研究.中国临床营养杂志,2005,3：137-141.
12.郭卫平,卫洪波,李玺.应用营养风险筛查2002评分系统对胃癌患者术前营养风险的评估.中华普外科杂志,2009,24(10).
13.徐兰娟,曹丽萍.结直肠癌患者的围手术期营养风险筛查与术后并发症.中国临床营养杂志,2009,17(1).
14.康维明,于健春,张群.胃肿瘤术后早期肠内营养的临床观察.外科理论与实践.2004,9(5).
15.王艳,蒋朱明,于康.临床营养的经济学研究进展.临床药物治疗杂志.2009,7(6).